SRPT Sarepta Therapeutics, Inc.
$18.89▲ +5.06%
Healthcare
Other
After hours
$18.90▲ +0.05%
Oct 27, 4:45 PM ET
Volume 2.23M
Avg Volume (10D) 3.19M
Key Metrics & Fundamentals
Market Cap
$2.00B
P/E Ratio
46.9
Div Yield
0.00%
52W Range
14.68 - 24.68
% vs 50 MA
-1.80%
% vs 200 MA
0.67%
RSI-14
53.9
MACD Histogram
+0.1800
Beta (1Y vs SPY)
2.05
Free Cash Flow
$196.52M
Gross Rev
$401.25M
Gross Profit
$251.87M
EBITDA
$69.62M
COGS
$149.39M
Operating Exp
$199.58M
Operating Income
$52.29M
EBIT
$52.29M
Pretax Income
-$1.75M
Net Income
-$4.89M
EPS (Diluted)
-0.05
Price & Volume History
Loading chart…
Recent News
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Business Wire · Oct 26, 2026 4:30 PM ET
Sarepta Therapeutics' PD Biomarker Data From FSHD, DM1 Studies Will Be in Focus, Wedbush Says
MT Newswires · Oct 26, 2026 11:35 AM ET
How Much Downside Is Left In Moderna Stock?
Trefis · Oct 23, 2026 4:00 AM ET
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
Business Wire · Oct 22, 2026 8:30 AM ET
Sarepta Therapeutics Faces New Growth Opportunity Emerging From SiRNA Programs, Wedbush Says
MT Newswires · Oct 16, 2026 12:01 PM ET
What Is The Case For Waiting On Moderna Stock?
Trefis · Oct 16, 2026 10:44 AM ET
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
Business Wire · Oct 14, 2026 8:30 AM ET
Where Could Moderna's Next Growth Come From?
Trefis · Oct 12, 2026 5:01 PM ET
Global Capsid Tropism Screening Platforms Market Report 2026 | Capitalize on 14.4% CAGR to $1.45B by 2030 as Sarepta, Voyager, REGENXBIO and Dyno Scale AI and NGS Screening
GlobeNewswire · Oct 12, 2026 9:59 AM ET
RBC Cuts Price Target on Sarepta Therapeutics to $17 From $19, Keeps Sector Perform, Speculative Risk
MT Newswires · Oct 8, 2026 7:23 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See SRPT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.